SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

neridronate

HOWL·Werewolf Therapeutics, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 3
Time to market
Topline Phase 3 results expected in 2028, NDA submission thereafter, potential FDA approval likely no earlier than 2029 if the trial succeeds.
Why 6/10
The next hard, dated catalyst is the interim analysis of the CRPS-RISE Phase 3 trial, announced in October 2026 following FDA feedback on a group sequential design that could allow early stopping. The interim analysis timing has not been specified but is expected within the next 6-12 months. Topline Phase 3 results are expected in 2028, with an NDA submission planned thereafter.
Actionable Insight NEUTRAL

Watch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.

Price Chart

Loading chart...

Executive Summary

Neridronate is an injectable bisphosphonate being developed by Ambros Therapeutics (merging into Werewolf Therapeutics/HOWL via reverse merger) for Complex Regional Pain Syndrome Type 1 (CRPS-1), a rare, debilitating pain condition with no FDA-approved treatments. The drug has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations. A pivotal Phase 3 trial (CRPS-RISE) began dosing in June 2026, and in October 2026 the company announced a planned interim analysis under a group sequential design. The combined company is expected to be funded through topline results in 2028 and into 2029. However, the reverse merger structure means massive dilution for current HOWL shareholders, and the drug still faces the binary risk of Phase 3 failure.

How It Works

Neridronate is a bisphosphonate, a class of drugs that slow bone breakdown by inhibiting osteoclast activity. In CRPS-1, a condition involving severe chronic pain often accompanied by bone loss and inflammation, neridronate is thought to reduce pain by normalizing bone metabolism and reducing inflammatory signaling in the affected limb.

Trial Status

The pivotal CRPS-RISE Phase 3 trial (group sequential design) began dosing its first patient in June 2026. In October 2026, Ambros announced a planned interim analysis following FDA feedback, using a group sequential design that could allow the trial to stop early. The trial is designed to support an FDA regulatory submission for neridronate in CRPS-1.

The Two-Sided Case

▲ Bull Case5
CRPS-1 affects roughly 65,000 newly diagnosed U.S. patients annually with no currently FDA-approved treatment, representing a large unmet need and potential orphan-drug commercial opportunity.
Neridronate has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, providing regulatory advantages including expedited review and potential market exclusivity.
The $150 million oversubscribed PIPE is expected to fully fund the company through Phase 3 topline results in 2028 and into the first half of 2029, reducing near-term dilution risk.
The group sequential design with interim analysis could allow the trial to stop early for efficacy, potentially accelerating the timeline to approval.
Several institutional investors (Jane Street, UBS, Renaissance Technologies) added or doubled positions in Q2 2026, and Barclays and LPL Financial added in Q3 2026.
▼ Bear Case5
Neridronate is still in Phase 3 with no topline data yet; Phase 3 trials in pain indications have a high historical failure rate.
Current HOWL shareholders will own only roughly 7% of the combined company post-merger, representing massive dilution for existing holders.
Analyst coverage is stale (last action December 2025) and the consensus is mixed: 3 hold, 1 sell, 2 strong sell ratings with a mean price target of $7 (though coverageStale flag is true).
RA Capital Management, a major holder, trimmed its position by 64% in Q2 2026, and several other funds also trimmed or exited.
Neridronate is an older bisphosphonate molecule originally developed by Grunenthal; prior Phase 3 programs by Grunenthal did not lead to U.S. approval, and the drug's efficacy in CRPS-1 has not been established in a pivotal U.S. trial.

Upcoming Catalysts

  • Interim analysis of the CRPS-RISE Phase 3 trial (timing not yet specified, announced October 2026)
  • Completion of the merger with Ambros Therapeutics and Nasdaq ticker change (expected to close after shareholder vote; S-4/A filed November 10, 2026)
  • Topline Phase 3 results expected in 2028
  • Potential NDA submission to the FDA following positive Phase 3 results

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Werewolf Therapeutics, Inc. 425 HOWL ·Originating report

Sources · 8

Hover a chip for the title
1 pulse2.com2 markets.businessinsider.com3 msn.com4 morningstar.com5 wboc.com6 fiercebiotech.com7 msn.com8 streetinsider.com